Cerliponase alfa · BRINEURA
Protein / enzyme therapeutic
Evidence outlook
Approved: Neuronal Ceroid Lipofuscinosis Type 2
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signalSingle-arm, accepted for approval (FDA label)
Also approved (2)
- Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2)
- Neuronal ceroid lipofuscinosis type 2 (CLN2) disease
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01907087 NCT01907087 · Neuronal Ceroid Lipofuscinosis Type 2 The study was a small, single-group, open-label trial with no randomization, blinding, or comparator arm. Although the clinical motor-language endpoint showed 87% responders among 23 analyzed participants, the uncontrolled design cannot establish how much of this outcome was due to cerliponase alfa. Registry: NCT01907087 | 1/2 | Motor-Language (ML) Scale Score During 300 mg Dosing Period (Baseline, Week 49/Last Assessment) 2015-11 | Motor-Language (ML) Scale Score During 300 mg Dosing Period (Baseline, Week 49/Last Assessment): 300 mg BMN 190 — Baseline: 3.5 units on a scale (Standard Deviation 1.2); Last Recorded Observation: 3.1 units on a scale (Standard Deviation 1.41); Change from Baseline to Last Recorded Observation: -0.4 units on a scale (Standard Deviation 0.84) | Weak signal | link ↗ |
View 2 more trials
NCT02485899 NCT02485899 · Neuronal Ceroid Lipofuscinosis Type 2 This was a single-group, open-label extension of Study 190-201, involving 23 treated participants and no randomized or blinded contemporaneous control; the comparison group was a 42-person natural-history cohort. The primary clinical function endpoints were statistically favorable versus natural history, but the uncontrolled extension design limits the strength of the evidence. Registry: NCT02485899 | 1/2 | Probability of Unreversed 2-point Decline in Motor-language (ML) Score or Score of 0 (Up to Week 289); Probability of Unreversed Motor-language (ML) Score of Zero. (Up to Week 289) 2020-12-10 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02678689 NCT02678689 · Neuronal Ceroid Lipofuscinosis Type 2 The study was a single-group, open-label treatment study rather than a randomized or blinded controlled trial; its comparison group came from historical natural-history data. Among 12 treated participants matched for analysis, the primary motor-language decline rate was 0.15 versus 1.30 points per 48 weeks in the natural-history group (p<0.0001), with other primary decline analyses also statistically favorable, but the design provides limited evidence because of the very small, nonrandomized sample. Registry: NCT02678689 | 2 | Motor Language (ML) Scale: Rate of Decline in the 0 to 6-point ML Score. (Baseline to Last assessment (Week 169)); Probability of Unreversed 2-Point Decline in Motor-language (ML) Score or Score of 0 (Baseline to Last assessment (Week 169)); Probability of Decline of Unreversed Motor-language (ML) Score of 0 (Baseline to Last assessment (Week 169)); Rate of Decline in Individual Motor Domains (Baseline to Last assessment (Week 169)); Rate of Decline in Individual Language Domains (Baseline to Last assessment (Week 169)) 2022-04-20 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.